Search

everythinglearnresearchcommunity

for

Search:↓

Managing seborrheic dermatitis using ketoconazole shampoo, Nizoral, and oils like MCT and coconut oil. The user considers shaving their head and consulting a dermatologist.

Several new hair loss treatments are in development, with Cosmo Breezula and Kintor KX826 being the furthest along, expected to be commercialized by 2027. Veradermics is the only treatment in pill form, while others like KX/GT/Breezula will be topical.

Hair follicles often go dormant rather than die, and treatments like minoxidil can help revive them. Scalp health and stimulation, such as massages and using products like sulphur soap, are also important for hair regrowth.

The conversation discusses various supplements and vitamins like Vitamin D3, K2, Biotin, Iron, Zinc, and B Vitamins for improving hair health. It also mentions a combination of Tocotrienols, Pycnogenol, Saw Palmetto, Pumpkin Seed Oil, Stinging Nettle, and Myricetin for stabilizing hair, with Saw Palmetto, Pygeum, and Stinging Nettle noted for thickening hair despite side effects.

Long-term finasteride use typically slows hair loss, with some users experiencing side effects like sexual dysfunction and depression. Many users also use minoxidil and dutasteride for improved results, though individual responses vary.

Hair loss treatments like Minoxidil, finasteride, and RU58841, focusing on their effectiveness and side effects. It also highlights the disparity in medical research funding between hair loss and conditions like endometriosis.

Minoxidil and finasteride have not improved the user's hairline after a year. Suggestions include trying dutasteride, microneedling, or considering a hair transplant for better results.

A serum with oleic and palmitoleic acids shows promise for hair regrowth in mice, but its effectiveness in humans is unproven. Minoxidil and finasteride remain the recommended treatments.

Sodium dodecyl sulfate, oleic acid, and palmitoleic acid may promote hair growth, but their safety and effectiveness for humans are uncertain. Users consider trying these treatments cautiously, exploring alternatives like ostrich oil and microneedling.

Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.

Hair provides protection against head trauma, reduces skin cancer risk, helps remove heavy metals, and aids in wound healing. The conversation emphasizes the health benefits of maintaining head hair beyond cosmetic reasons.

PP405 is a new hair loss treatment targeting dormant hair follicles, with ongoing trials. Some users consider stopping finasteride and minoxidil to join trials, while others doubt its effectiveness.

The conversation discusses reducing scalp DHT to prevent hair loss, with a focus on using dutasteride, finasteride, and other treatments like RU58841 and minoxidil. It highlights the challenges of managing hair loss while on high testosterone levels, suggesting that dutasteride may be more effective than finasteride in such cases.

DHT may inhibit hair growth by affecting mitochondrial function, leading to hair follicle miniaturization. Treatments like minoxidil and PP405 may promote hair growth by altering metabolic pathways, potentially counteracting DHT's effects.

Federal funding cuts have delayed PP405 research, affecting hair loss treatment progress, though clinical trials will continue. The discussion highlights PP405's potential compared to minoxidil and finasteride and stresses the importance of government-funded research.

A 30-year-old man shared his positive experience with hair regrowth using Regenera Activ, topical Dutasteride, Minoxidil, and PRP over 12 weeks. He plans to continue with injectable Dutasteride and emphasizes the importance of starting treatment early to combat hair loss.

Hair cloning technology is advancing, with clinical trials for improved methods expected by 2028 and 2029, potentially offering a solution for hair loss if donor follicles remain. Organtech's expansion into other biotech areas may secure funding, but the effectiveness of cloning depends on the availability of androgen-resistant donor follicles.

The user is using a combination of 7% minoxidil, 0.2% finasteride, 0.5mg finasteride, RU58841, and daily microneedling but is not seeing hair regrowth after 5 months. Suggestions include being patient, reducing microneedling frequency, considering oral minoxidil, and possibly switching to dutasteride if no improvement after a year.

Creatine is unlikely to worsen hair loss for those on finasteride, with no strong scientific evidence linking it to increased hair loss. Many users report no negative effects on hair while using creatine.

PP405 significantly improves hair density, outperforming finasteride, with 31% of users seeing over 20% improvement in four weeks. Concerns exist about its availability, cost, and long-term effects.

PP405 shows promise in treating severe hair loss, with 31% of users experiencing over 20% hair density increase in four weeks, faster than minoxidil and finasteride. Some users are skeptical about the results' significance and long-term efficacy.

PP405 is a new drug in Phase 2 trials for hair loss, generating cautious optimism among users. Some users are currently using finasteride and experiencing side effects, while others are skeptical about unapproved products being sold.

Recruitment for a verteporfin trial and a separate hair cloning trial using verteporfin and other methods is underway, with locations in Jordan, NYC, Beverly Hills, and Memphis. Dr. Bloxham is conducting the hair cloning trial, and interested participants are encouraged to contact him directly.

PP405 is a promising new treatment for hair loss that activates dormant stem cells in hair follicles, potentially bypassing the effects of DHT. It is currently in phase 2 trials and could be available between 2027 and 2030, but it is not considered a definitive cure.

An 18-year-old shares their successful hair regrowth journey using finasteride 1mg daily, topical minoxidil twice a day (mixed with tretinoin 0.025% at night), ketoconazole shampoo 2-3 times a week, and occasional dermarolling. They report no side effects and emphasize the importance of consistency and early intervention.

AI advancements, like AlphaFold, are speeding up drug discovery for hair loss, promising more effective treatments. Current options like minoxidil and finasteride have limitations, but new developments could improve solutions in 5-10 years.

Finasteride and Dutasteride do not cause dry eyes by damaging meibomian glands, as these glands continue to function normally even when DHT is blocked. Some users report dry eyes with these medications, but others suggest supplements like Omega-3 or krill oil as potential remedies.

Minoxidil is harmful to pets, especially cats, if they contact it. Users recommend switching to oral minoxidil or taking precautions like washing hands and using head coverings to prevent exposure.

Topical finasteride can be as effective as oral finasteride for hair regrowth with fewer systemic side effects, but precise dosing is essential. Combining oral dutasteride with topical finasteride is not recommended due to dutasteride's stronger inhibition.

The individual had a hair transplant in Turkey with 4052 grafts, resulting in significant hair growth and increased confidence. They use finasteride, rosemary oil, and vitamins, and are pleased with the natural-looking results, encouraging others to consider similar treatments.